Evaluation of the rapid antigen detection test STANDARD F COVID-19 Ag FIA for diagnosing SARS-CoV-2: experience from an Emergency Department

Diagn Microbiol Infect Dis. 2022 Jun;103(2):115683. doi: 10.1016/j.diagmicrobio.2022.115683. Epub 2022 Mar 18.

Abstract

The purpose of this study was to assess the clinical performance of STANDARD F COVID-19 Ag FIA (SD Biosensor Inc., Gyeonggi-do, Republic of Korea), a rapid antigen detection test (RADT) for diagnosing SARS-CoV-2, in patients attended at the Emergency Department with signs or symptoms compatible with COVID-19 that had started in the last 5 days. The clinical performance of the antigen test was compared with RT-PCR, the reference standard. We included 663 specimens from non-repetitive patients. Clinical sensitivity and specificity were 84.0% (95% CI 76.1-89.7) and 99.6% (95% CI 98.5-99.9), respectively. The positive and negative predictive values were 98.1% (95% CI 92.7-99.7) and 96.4% (95% CI 94.4-97.7), respectively. The kappa index agreement between RT-PCR and the RADT was 0.89 (95% CI 0.84-0.93). We concluded that STANDARD F COVID-19 Ag FIA is an excellent first-line RADT method to diagnose symptomatic patients in the emergency department.

Keywords: COVID-19; Emergency Department; Rapid antigen test; SARS-CoV-2.

MeSH terms

  • Antigens, Viral / analysis
  • COVID-19 Serological Testing
  • COVID-19* / diagnosis
  • Emergency Service, Hospital
  • Humans
  • SARS-CoV-2*
  • Sensitivity and Specificity

Substances

  • Antigens, Viral